Autolus Therapeutics (AUTL) Aktienübersicht
Autolus Therapeutics plc, ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt T-Zell-Therapien zur Behandlung von Krebs und Autoimmunkrankheiten im Vereinigten Königreich und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
AUTL Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Autolus Therapeutics plc Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$1.70 |
| 52-Wochen-Hoch | US$2.70 |
| 52-Wochen-Tief | US$1.18 |
| Beta | 1.93 |
| 1 Monat Veränderung | 6.25% |
| 3 Monate Veränderung | 1.80% |
| 1 Jahr Veränderung | 10.39% |
| 3 Jahre Veränderung | -39.93% |
| 5 Jahre Veränderung | -74.36% |
| Veränderung seit IPO | -93.20% |
Aktuelle Nachrichten und Updates
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.Recent updates
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.AUTL: Lower 2026 Sales Guidance Will Still Support Upside Potential
Analysts have trimmed their price targets on Autolus Therapeutics by $2 to $3 following updated 2026 Aucatzyl sales guidance of $120M to $135M, as well as a recalibration of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research notes highlight a mixed but focused view on Autolus Therapeutics, centered on execution against updated Aucatzyl sales guidance, cost structure, and how these flow through to valuation assumptions.Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Summary Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential. Competitive pressures, funding needs beyond 2027, and uncertain commercial uptake in cell therapy remain material risks for AUTL. Read the full article on Seeking AlphaThe Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders won't be pleased to see that the share price has had a very rough...Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Autolus Therapeutics plc ( NASDAQ:AUTL ) shares have had a really impressive month, gaining 28% after a shaky period...Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Celebrations may be in order for Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders, with the analysts delivering a...Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Summary Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth. Read the full article on Seeking AlphaAutolus Therapeutics Will Remain Depressed For A While
Summary Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism. Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising. AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt. The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years. Read the full article on Seeking AlphaIs Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Summary Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company’s Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. Key risks include scaling manufacturing, securing insurance coverage, and expanding treatment centers, but these are manageable, supporting a bullish long-term outlook. Autolus's valuation appears undervalued given AUCATZYL's market potential and robust pipeline, including multiple CAR T-cell therapies in various trial stages. Read the full article on Seeking AlphaAutolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Summary Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. An intriguing secondary catalyst is obe-cel in autoimmune disease systemic lupus erythematosus - positive data could send the share price soaring. I have followed Autolus for some time, and my “buy” calls have not come off — but I remain optimistic there is a cell therapy player of note here and I am keeping the faith. Read the full article on Seeking AlphaIs Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Autolus Therapeutics: Major Inflection Point On The Horizon
Summary Today, we are putting T cell developmental firm Autolus Therapeutics plc back in the spotlight for the first time in a year and a half. The company could garner its first FDA approval later this year, and recently signed an enhanced partnership arrangement with a large player in the biotech space. An updated analysis around Autolus Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaAutolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the November action date to realize it. Read the full article on Seeking AlphaWe're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Aktionärsrenditen
| AUTL | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 4.3% | 1.2% | 1.0% |
| 1Y | 10.4% | 34.9% | 28.7% |
Rendite im Vergleich zur Industrie: AUTL unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 34.9% erzielte.
Rendite vs. Markt: AUTL hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 28.7 erzielte.
Preisvolatilität
| AUTL volatility | |
|---|---|
| AUTL Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: AUTL hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: AUTLDie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2014 | 753 | Chris Itin | www.autolus.com |
Autolus Therapeutics plc, ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt T-Zell-Therapien für die Behandlung von Krebs und Autoimmunerkrankungen im Vereinigten Königreich und auf internationaler Ebene. Das Unternehmen bietet AUCATZYL an, ein Gentherapieprodukt, das aus körpereigenen T-Zellen besteht, die mit einem lentiviralen Vektor transduziert werden, um einen neuartigen chimären Anti-CD19-Antigenrezeptor zu exprimieren. Es entwickelt auch obe-cel, das sich in Phase 1 zur Behandlung von systemischem Lupus erythematodes, progressiver Multipler Sklerose, B-NHL und CLL sowie ZNS-Lymphomen befindet; obe-cel, das sich in Phase 2 zur Behandlung von pädiatrischer B-ALL und Lupusnephritis befindet; AUTO1/22 zur Behandlung von pädiatrischer B-ALL, das sich in Phase 1 befindet; AUTO8, das sich in der Phase 1 zur Behandlung des multiplen Myeloms und der Leichtketten-Amyloidose befindet; AUTO4/5, das sich in der präklinischen Phase zur Behandlung von peripherem TCL befindet; AUTO6NG, das sich in der Phase 1 zur Behandlung von Neuroblastom befindet; und AUTO9, das sich in der präklinischen Phase zur Behandlung von akuter myeloischer Leukämie befindet.
Autolus Therapeutics plc's Grundlagenzusammenfassung
| AUTL grundlegende Statistiken | |
|---|---|
| Marktanteil | US$439.14m |
| Gewinn(TTM) | -US$288.96m |
| Umsatz(TTM) | US$92.62m |
Ist AUTL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| AUTL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$92.62m |
| Kosten der Einnahmen | US$208.48m |
| Bruttogewinn | -US$115.85m |
| Sonstige Ausgaben | US$173.11m |
| Gewinn | -US$288.96m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.09 |
| Bruttomarge | -125.08% |
| Nettogewinnspanne | -311.98% |
| Schulden/Eigenkapital-Verhältnis | 325.9% |
Wie hat sich AUTL auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 19:02 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Autolus Therapeutics plc wird von 16 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |